Macrolide compound having Anti-inflammatory activity, and preparation method therefor and use thereof
The macrolide compounds obtained by fermenting from the intestinal fungus Talaromyces rugulosus GIZ45-A37 of the bat moth have solved the problem of severe inflammatory response in patients with COPD, achieved significant anti-inflammatory activity and safety, and had the potential to develop anti-inflammatory drugs. .
Patent Information
- Application Number
- PCT/CN2024/080342
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-12-14
- Filing Date
- 2024-03-06
- Publication Date
- 2024-11-07
AI Technical Summary
Patients with chronic obstructive pulmonary disease (COPD) have long suffered from severe inflammatory reactions, existing therapeutic drugs have drug resistance and adverse reactions, and the lack of safe and effective anti-inflammatory drugs, which has increased the difficulty of treatment.
The fungal strain Talaromyces rugulosus GIZ45-A37 was isolated from the intestine of the bat moth, and a macrolide compound was obtained by fermentation, and purified by ethyl acetate extraction and column chromatography to produce a compound with significant anti-inflammatory activity. .
In vitro experiments, this compound significantly reduces the production of LPS-induced inflammatory mediator IL-6, has good anti-inflammatory activity, and is simple in preparation steps, is easy to be industrialized and mass-produced, and has broad application prospects.
Smart Images

Figure CN2024080342_07112024_PF_FP_ABST
Abstract
Description
A macrolide compound with anti-inflammatory activity and its preparation method and application Technical field:
[0001] The present invention belongs to the technical field of natural medicines, and in particular relates to a macrolide compound with anti-inflammatory activity, a preparation method and an application thereof. Background technology:
[0002] Chronic obstructive pulmonary disease (COPD) is a chronic airway inflammatory disease characterized by airflow limitation and progressive decline in lung function, severely impacting patients' ability to work and quality of life. It is a heterogeneous, systemic disease that progressively worsens and is not fully reversible in modern society. It is the third leading cause of death worldwide and has risen to fifth place in the world's economic burden. Globally, COPD prevalence exceeds 8%, with a preponderance in developing countries. With over 100 million patients in my country, COPD places a heavy burden on patients, their families, and society.
[0003] COPD is primarily associated with long-term exposure to harmful gases such as chemical particles or cigarette smoke, leading to nonspecific chronic inflammatory reactions in the bronchial mucosa, blood vessels, and alveoli. COPD also has a high mortality rate in my country, especially during acute exacerbations of COPD (AECOPD). Patients experience severe inflammatory reactions in the respiratory tract, which further aggravates irreversible airway obstruction, respiratory muscle fatigue, and often progresses to type II respiratory failure, further increasing the mortality rate and making clinical treatment more difficult. With the further aggravation of environmental pollution and the accelerated aging of the Chinese population, the incidence of COPD has been increasing year by year. Commonly used COPD treatment drugs, such as β-agonists and anticholinergics, can often only alleviate clinical symptoms and have certain drug resistance and adverse reactions. Therefore, the development of new, safer and more effective drugs is needed.
[0004] Nature is rich in fungal resources, and fungi have a vast gene pool, offering the potential for synthesizing novel and highly active compounds. This makes them an important avenue for developing natural pharmaceutically active ingredients. The present invention isolated a fungus strain from the intestines of bat moths, identified as Talaromyces rugulosus. Currently, there are very few reports on this strain, and no reports on its metabolites. The inventors conducted preliminary research on the metabolites of this fungus, aiming to discover lead compounds with novel structures and significant anti-inflammatory activity.
[0005] Summary of the invention:
[0006] The purpose of the present invention is to provide a bat moth intestinal endophytic bacteria strain and a new compound with significant anti-inflammatory activity obtained by fermenting the strain.
[0007] [Corrected on 21.03.2024 according to Rule 26] The present invention provides a bat moth intestinal endophyte strain Talaromyces rugulosus GIZ45-A37, which is preserved in Guangdong Provincial Microbial Culture Collection Center (GDMCC), address: Guangdong Institute of Microbiology, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Postal Code: 510075, and the preservation number is GDMCC No: 64050.
[0008] The present invention provides a compound represented by Formula I, or a pharmaceutically acceptable salt or solvate thereof:
[0009] Wherein, R1, R2, R3, and R4 are independently selected from hydrogen or hydroxyl.
[0010] Furthermore, the above R1 is a hydroxyl group.
[0011] Furthermore, the above R2 is a hydroxyl group.
[0012] Furthermore, the above R3 is a hydroxyl group.
[0013] Furthermore, the above R4 is a hydroxyl group.
[0014] Furthermore, the structure of the above compound is as follows:
[0015] The present invention also provides a method for preparing the above compound, which comprises the following steps:
[0016] S1. inoculating Talaromyces rugulosus into a fermentation medium and culturing to obtain a fermentation product;
[0017] S2, adding ethyl acetate to the fermentation product obtained in S1, mixing, extracting, and filtering to obtain an extract;
[0018] S3, concentrating the extract obtained in S2 under reduced pressure to obtain a crude extract;
[0019] S4. The crude extract obtained in S3 was subjected to silica gel column chromatography, and gradient elution was performed with an eluent consisting of petroleum ether and ethyl acetate in a volume ratio of petroleum ether to ethyl acetate of 50:1, 25:1, 10:1, 5:1, 2:1, and 1:1, respectively. The eluate with a volume ratio of petroleum ether to ethyl acetate of 2:1 was collected and dried to obtain a crude product;
[0020] S5. The crude product obtained in S4 is subjected to reverse-phase ODS column chromatography, and gradient elution is performed with an eluent consisting of methanol and water, with a methanol concentration of 20%, 40%, 60%, and 80% in sequence, and the eluate with 40% methanol is collected and dried to obtain a crude product;
[0021] S6. The crude product obtained in S5 was subjected to gel Sephadex LH20 column chromatography using methanol as the eluent, and the eluent was collected for high performance liquid chromatography (HPLC) using a C18 column, 60% methanol / water, and a wavelength of 254 nm as the chromatographic conditions. The eluent containing the main peak was collected and dried to obtain a crude product.
[0022] S7. Purify the crude product obtained in S6 by medium- and high-pressure preparative liquid phase purification.
[0023] Furthermore, the fermentation medium described in step S1 above is composed of the following components in parts by weight: 90-100 g of rice and 100 ml of water.
[0024] Preferably, the culturing in step S1 is performed by placing the culture medium at a constant temperature of 25° C. for 30 days;
[0025] Preferably, the extraction conditions in step S2 are as follows: a mass volume ratio of culture medium to ethyl acetate of 1:3, ultrasonic extraction for 15 min, three extractions, a power of 400 W for ultrasonic extraction, and an operating frequency of 40 kHz;
[0026] Preferably, the mobile phase for the high pressure preparative liquid chromatography purification in step S7 is a mixed solution of methanol and water, wherein the volume percentage of methanol is 80%.
[0027] The present invention also provides use of the above compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof in the preparation of an anti-inflammatory drug.
[0028] Preferably, the drug is a drug for preventing and treating chronic obstructive pulmonary disease (COPD).
[0029] The present invention also provides a medicine, which is a preparation prepared by using the above-mentioned compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient, and adding pharmaceutically acceptable excipients or auxiliary ingredients.
[0030] Beneficial effects of the present invention:
[0031] (1) The bat moth intestinal endophytic bacteria strain of the present invention can ferment to produce a new compound. The macrolide compound provided by the present invention has been confirmed by in vitro pharmacological experiments to significantly reduce the production of LPS-induced inflammatory mediator IL-6 at a concentration of 10 μM, indicating that it has good anti-inflammatory activity. Therefore, the macrolide compound can be used in anti-inflammatory drugs. The compound can be obtained by extracting the fermentation product of the aforementioned strain with ethyl acetate and then separating and purifying it by column chromatography and high-performance liquid chromatography. The separation steps are simple, the implementation is convenient, and it is easy to industrialize and mass-produce, and it has broad application prospects.
[0032] (2) The compound of the present invention is produced by solid fermentation of fungi and can be obtained by extracting the fermentation product with ethyl acetate and then separating and purifying it by silica gel column chromatography, reversed-phase ODS column chromatography, gel column chromatography and high-performance liquid chromatography. The separation steps are simple, the implementation is convenient, and it is easy to industrialize and mass-produce, and it has broad application prospects.
[0033] Deposit of biological materials:
[0034] Talaromyces rugulosus GIZ45-A37 was deposited on November 22, 2023 in Guangdong Microbiological Culture Collection Center (GDMCC), address: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Postal Code: 510070, with the deposit number GDMCC No: 64050.
[0035] Obviously, based on the above contents of the present invention, according to common technical knowledge and customary means in this field, without departing from the above basic technical ideas of the present invention, other various forms of modifications, replacements or changes can be made.
[0036] The following further describes the above content of the present invention in detail through specific embodiments in the form of examples. However, this should not be construed as limiting the scope of the above subject matter of the present invention to the following examples. All technologies implemented based on the above content of the present invention fall within the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] FIG1 is a high-resolution mass spectrometry result graph of the compound having the structure of Formula I of the present invention.
[0038] FIG2 is a diagram of a compound having a structure of formula I according to the present invention. 1 H NMR spectrum.
[0039] FIG3 is a diagram of a compound having a structure of formula I according to the present invention. 13 C NMR spectrum.
[0040] FIG4 is a diagram of a compound having a structure of formula I according to the present invention. 1 H- 1 H COSY spectrum.
[0041] FIG5 is a HSQC spectrum of the compound having the structure of Formula I of the present invention.
[0042] FIG6 is the HMBC spectrum of the compound having the structure of Formula I of the present invention.
[0043] FIG7 shows the cell growth rate at different concentrations of the compound having the structure of Formula I of the present invention.
[0044] FIG8 is the result of IL-6 content determination of the anti-inflammatory activity of the compound having the structure of Formula I of the present invention. Specific implementation method:
[0045] The following examples are provided to further illustrate the present invention, but are not intended to limit the present invention.
[0046] Example 1: Identification of the endophytic fungus strain Talaromyces rugulosus of the present invention
[0047] [Corrected 21.03.2024 according to Rule 26] The present invention's Talaromyces rugulosus GIZ45-A37 was isolated from the intestine of the bat moth and deposited in the Guangdong Provincial Microbial Culture Collection Center (GDMCC), address: Guangdong Institute of Microbiology, Building 59, No. 100 Xianlie Middle Road, Guangzhou, Postal Code: 510075, and the deposit number is GDMCC No: 64050.
[0048] Based on the DNA sequence of the internal transcribed spacer (ITS) region (SEQ ID NO. 1), the fungal strain was identified as Talaromyces rugulosus by NCBI BLAST analysis.
[0049] The following sequence was used in the BLAST search. SEQ ID NO. 1:
[0050] Example 2. Preparation of the compound of the present invention
[0051] 1. Fermentation of bacteria
[0052] 1. Inoculate the strain Talaromyces rugulosus onto a PDA culture medium plate and culture in the dark at 28°C for 7 days to obtain plate seeds.
[0053] 2. Transfer the slant seeds obtained in step 1 to liquid seed culture medium and culture in the dark at 28°C and 150 rpm for 4 days to obtain seed culture solution.
[0054] Seed culture medium: The solvent is potato juice (potato juice preparation method: 200g potatoes, add about 1L of water, boil for 30min, filter, and make up the filtrate to 1L), the solute and its content are as follows: glucose 20g / L, agar 20g.
[0055] 3. Inoculate approximately 10 mL of seed culture solution into a flask containing fermentation medium and culture at a constant temperature of 25°C for 30 days.
[0056] 4. Preparation of fermentation medium: Take 100g of rice, add 100ml of water, put it into a 500mL Erlenmeyer flask, and sterilize it under high pressure (120℃, 20min).
[0057] 2. Extraction, separation and purification of the compounds of the present invention
[0058] 1. Add 300 ml of ethyl acetate to the fermented flask, perform ultrasonic extraction at 30°C for 15 min, extract three times, with an ultrasonic power of 400 W and an operating frequency of 40 kHz, filter the extract, combine all the extracts and concentrate under reduced pressure at 40°C to obtain a total extract.
[0059] 2. After the total extract and silica gel are stirred and evenly mixed in a ratio of 1:1, the sample is dry loaded and subjected to silica gel column chromatography (the filler used in the silica gel column chromatography is 200-300 mesh column chromatography silica gel) with petroleum ether / ethyl acetate (the volume ratios of petroleum ether and ethyl acetate are 50:1, 25:1, 10:1, 5:1, 2:1, 1:1, and pure ethyl acetate, respectively). The eluate with a volume ratio of petroleum ether and acetone of 2:1 is collected and rotary evaporated to obtain dry matter A.
[0060] 3. Dry matter A was further eluted with a reverse column (filler: ODS C-18 column chromatography silica gel, gradient elution, eluent: methanol / water mixed solvent, eluted with 20%, 40%, 60%, and 80% methanol / water in sequence, eluting with 2 column volumes of solvent respectively, collecting the 40% methanol / water eluate, and concentrating under reduced pressure to dryness to obtain dry matter A-1.
[0061] 4. The dry matter A-1 was further separated by gel column chromatography on Sephadex LH-20 with methanol as the eluent. The eluent was collected and the fractions were analyzed by HPLC using a C18 column, 60% methanol / water by volume as the eluent, a flow rate of 0.5 ml / min, and a wavelength of 254 nm. The eluent containing the main peak (retention time 6.52 min) was collected and dried to obtain the crude product A-2. The product was purified by medium- and high-pressure preparative liquid chromatography (1 mL / min, 80% methanol / water, v / v) to obtain a white powder. Characterization data are as follows:
[0062] Figure 1 is a high-resolution mass spectrometry result of a compound having a structure of Formula I according to the present invention. Figure 2 is a high-resolution mass spectrometry result of a compound having a structure of Formula I according to the present invention. 1 H NMR spectrum. Figure 3 is a graph of the compound of formula I of the present invention. 13 C NMR spectrum. Figure 4 is a graph of the compound having the structure of formula I of the present invention. 1 H- 1 H COSY spectrum. Figure 5 is the HSQC spectrum of the compound having the structure of Formula I of the present invention. Figure 6 is the HMBC spectrum of the compound having the structure of Formula I of the present invention.
[0063] 5.HR-ESI-MS:m / z 523.23024[M+Na] + (Figure 1)
[0064] 1 H NMR (600MHz, CDCl3): δ1.22(3H,s,H-13),1.23(3H,s,H-13′),1.50,1.61(2H,m,H-10),1. 72,1.62(2H,m,H-10′),1.53(4H,m,H-11,11′),1.94,1.77(4H,m,H-9,9′),2.94(4H,m,H- 7,7′), 3.84(2H,m,H-6,6′), 4.59(2H,m,H-8,8′), 6.69(2H,d,J=8.4Hz,H-10,10′), 6.89(2H,d,J=8.4Hz,H-9,9′), 7.41(2H,dd,J=8.4Hz,8.4Hz,H-11,11′), 11.00(2H,s,OH), see Figure 2.
[0065] 13 C NMR (150MHz, CDCl3): δ21.21(C-10),21.36(C-10′),23.81(C-13,13′),33.02(C-7),3 3.06(C-7′),34.84(C-9),34.93(C-9′),38.86(C-11),38.96(C-11′),67.95(C-12),68 .00(C-12′),79.69(C-8),79.77(C-8′),108.58(C-2,2′),116.34(C-6,6′),118.09(C-4,4′),136.28(C-5,5′),139.54(C-3,3′),162.27(C-1,1′),170.06(C-14,14′), see Figure 3.
[0066] The molecular formula is C 28 H 36 O8, the structure is as follows:
[0067] Example 3: Anti-inflammatory activity test of the compounds of the present invention
[0068] COPD is a disease associated with long-term chronic inflammatory stimulation, which can lead to overexpression of inflammatory factors and altered immune function. During acute attacks, multiple inflammatory factors are continuously released in large quantities, causing severe deterioration of the disease and subsequently affecting the overall treatment effect (Gao J, Wu S, Lin W, et al. Blood cells for the differentiation of AECOPD airway inflammatory phenotypes[J]. Basic clin pharmacol toxicol. 2019, 125(SI):57-58.). Interleukin-6 (IL-6) is an important inflammatory factor, and increased IL-6 expression promotes the development of inflammation. Studies have found that IL-6 levels are elevated in the blood, sputum, and bronchoalveolar lavage fluid of COPD patients, and their soluble IL-6 receptors are also increased. Therefore, IL-6 can be used as an indicator of inflammatory development and may also be a potential target for COPD treatment (Winslow S, Odqvist L, Diver S, et al. Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and Haemophilus infection in COPD[J]. Eur Respir J. 2021, 58(4): 1-14.). The present invention acts on lipopolysaccharide (LPS)-induced human bronchial epithelial cells Beas2b by subjecting the compound prepared in Example 1 (hereinafter referred to as DMX) to the anti-inflammatory activity of DMX by detecting the IL-6 content produced in the cell culture supernatant.
[0069] 1. Reagents and Instruments
[0070] Human bronchial epithelial cells Beas-2b; lipopolysaccharide (LPS); DMEM high-glucose medium; fetal bovine serum (FBS); phosphate-buffered saline (PBS); dimethyl sulfoxide (DMSO); 1% P / S double-antibody; enzyme-linked immunosorbent assay kit (ELISA kit); precision electronic balance; biological safety cabinet; carbon dioxide incubator; inverted microscope; low-speed refrigerated centrifuge; microplate reader; digital constant-temperature water bath.
[0071] 2. Culture of Beas-2b cells
[0072] The basal culture medium is DMEM culture medium + 10% FBS + 1% P / S double antibody; the culture conditions are 37°C, 5% CO2 and saturated humidity; after culturing for 2 to 3 days, the cell density reaches 90% and can be used for experiments.
[0073] 3. Cell Viability Assay
[0074] Beas-2b cells in the logarithmic growth phase were taken and prepared into 2×10 5 A single-cell suspension of 100 μl / well of cells was seeded into 96-well plates (three replicates per group). After the cells attached, they were cultured until approximately 80% confluency. The original culture medium was discarded. The control group was treated with normal culture medium (1 μl of compound solution and 99 μl of DEME medium). The DMX group was treated with culture medium containing different concentrations of compound (1 μl of compound solution and 99 μl of DEME medium, with final DMX concentrations of 25 μM, 12.5 μM, 6.25 μM, 3 μM, and 1.5 μM). The cells were cultured for 24 hours. Cell growth and changes in the culture medium were observed under an inverted microscope. After the incubation period, 10 μl of CCK-8 working solution was added to each well, incubated at 37°C for 2 hours, and detected at 450 nm.
[0075] Cell inhibition rate = 1-(drug-added well-background value) / (control well-background value) × 100%
[0076] The experimental results are shown in Figure 7: DMX has no significant inhibitory effect on Beas2b cells within the concentration range of 1.5 μM to 25 μM, indicating that DMX is safe within this range.
[0077] 4. Determination of the anti-inflammatory activity of compound DMX
[0078] Beas-2b cells in the logarithmic growth phase were taken and the cell density was adjusted to 2×10 6 Cells were seeded into a 48-well plate at a volume of 500 μl / well. After the cells adhered, they were cultured until the confluence reached about 80%. The culture medium was discarded. A control group, a model group, and a DMX group were set up. LPS and DMX were not added to the control group. LPS solution was added to the culture medium of the model group (the final concentration of LPS was 1 μg / ml). Fresh DMEM culture medium containing LPS and DMX solution was added to the DMX group (the final concentration was 10 μM). The culture was continued for 24 hours. After the culture was completed, the supernatant of each well was collected into a 1.5 ml centrifuge tube and centrifuged at 6000 rpm for 5 minutes. The supernatant was transferred to another 1.5 ml centrifuge tube and stored at -20°C for ELISA detection. The IL-6 content was detected according to the instructions of the ELISA kit.
[0079] The experimental data were expressed as mean ± standard deviation (x ± s), and the inter-group comparisons were performed using SPSS 22.0 statistical software for one-way analysis of variance for significant differences. *p < 0.05 and **p < 0.01 were used to indicate significant differences between the model group and the control group, respectively; # p<0.05,## p<0.01 indicates a significant difference and is statistically significant.
[0080] As shown in Figure 8, the IL-6 content in the model group was significantly different from that in the control group, indicating that the model was successfully established. The IL-6 content in the DMX group was significantly lower than that in the model group, indicating that DMX has the ability to inhibit IL-6 expression activity, thereby exerting an anti-inflammatory effect.
[0081] Chronic obstructive pulmonary disease (COPD) is a chronic disease closely related to inflammation. Suppressing the progression of inflammation is an important method and approach for treating COPD. The compound DMX of the present invention exhibits significant anti-inflammatory activity at concentrations as low as 10 μM, and cell viability experiments show essentially no cytotoxicity. Therefore, the compound DMX of the present invention has the potential to be developed as a drug for the treatment of COPD.
Claims
1. Talaromyces rugulosus GIZ45-A37, deposited with GDMCC No: 64050.
2. A macrolide compound having anti-inflammatory activity, or a pharmaceutically acceptable salt thereof, or a solvate thereof, characterized in that: The structural formula is shown in (Ⅰ): Wherein, R1, R2, R3, and R4 are independently selected from hydrogen or hydroxyl.
3. The compound according to any one of claim 2, or a pharmaceutically acceptable salt thereof, or a solvate thereof, characterized in that: The structure of the compound is as follows:
4. A method for preparing the compound according to claim 3, characterized in that: It includes the following steps: S1. Inoculating the Schizotypalmatine sp. GIZ45-A37 according to claim 1 into a fermentation medium, and culturing to obtain a fermentation product; S2, adding ethyl acetate to the fermentation product obtained in S1, mixing, extracting, and filtering to obtain an extract; S3, concentrating the extract obtained in S2 under reduced pressure to obtain a crude extract; S4, subjecting the crude extract obtained in S3 to silica gel column chromatography, using an eluent consisting of petroleum ether and ethyl acetate, and performing gradient elution in a volume ratio of petroleum ether to ethyl acetate of 50:1, 25:1, 10:1, 5:1, 2:1, and 1:1 in sequence, collecting the eluent with a volume ratio of petroleum ether to ethyl acetate of 2:1, and drying to obtain a crude product; S5, subjecting the crude product obtained in S4 to reverse phase ODS column chromatography, using an eluent consisting of methanol and water, and performing gradient elution in the order of methanol concentrations of 20%, 40%, 60%, and 80%, collecting the eluate with 40% methanol, and drying to obtain a crude product; S6, subjecting the crude product obtained in S5 to gel Sephadex LH20 column chromatography, using methanol as an eluent, collecting the eluent for high performance liquid chromatography detection, using a C18 chromatographic column, 60% methanol / water, and a wavelength of 254 nm as chromatographic conditions for detection, collecting the eluent containing the main peak, and drying to obtain a crude product; S7, purifying the crude product obtained in S6 by medium- and high-pressure preparative liquid phase.
5. The preparation method according to claim 4, characterized in that: The fermentation medium described in step S1 is 90-100g of rice added to every 100ml of water; the culture described in step S1 is placed at a constant temperature of 25°C and cultured for 30 days; the extraction conditions described in step S2 are that the mass volume ratio of the culture medium to ethyl acetate is 1:3, the ultrasonic extraction is 15min, the number of extractions is 3 times, the power used for the ultrasonic extraction is 400W, and the operating frequency is 40KHz; the mobile phase for the medium and high pressure preparative liquid chromatography purification described in step S7 is: a mixed solution of methanol and water, wherein the volume percentage of methanol is 80%.
6. Use of the compound according to any one of claims 2 to 3, or a pharmaceutically acceptable salt thereof, or a solvate thereof in the preparation of an anti-inflammatory drug.
7. The use according to claim 6, characterized in that: The medicine is a medicine for preventing and treating chronic obstructive pneumonia.
8. A medicine, characterized in that: The invention relates to a preparation prepared by taking the compound described in any one of claims 2 to 3, or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient, and adding pharmaceutically acceptable excipients or auxiliary ingredients.
9. The use according to claim 6, characterized in that: The medicine is a medicine for preventing and treating chronic obstructive pneumonia.
Citation Information
Patent Citations
Excoecaria agallocha endophytic fungi sourced polyketide compound and application thereof to preparation of anti-inflammatory drug
CN108315264A
Preparation method of compound Cyophiobilins A-B and application of compound Cyophiobilins A-B in preparation of anti-inflammatory drugs
CN115181083A
Water-soluble red edible fungal pigment with anti-inflammatory activity as well as preparation method and application thereof
CN115215902A
Endophytic fungus source-based pyrone compound as well as preparation method and application thereof
CN116836139A
Treatment Of Inflammatory Lung Conditions With Aerosolized Macrolide Antibiotics
US20100029551A1
Cited By
Alpinia zerumbet endophytic fungus-derived sesquiterpenoids, and preparation method and application thereof
CN119823086A
